Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Zealand Pharma A/S (NASDAQ:ZEAL) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 54 0.00 34.37M -3.74 0.00
Zealand Pharma A/S 30 0.00 26.77M 3.00 7.54

Table 1 highlights CRISPR Therapeutics AG and Zealand Pharma A/S’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has CRISPR Therapeutics AG and Zealand Pharma A/S’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 63,507,021.43% -50.9% -39.8%
Zealand Pharma A/S 87,914,614.12% 0% 0%

Analyst Recommendations

CRISPR Therapeutics AG and Zealand Pharma A/S Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 4 3.00
Zealand Pharma A/S 0 0 2 3.00

CRISPR Therapeutics AG has a consensus price target of $66.5, and a -8.11% downside potential. On the other hand, Zealand Pharma A/S’s potential upside is 11.04% and its consensus price target is $36.5. The results provided earlier shows that Zealand Pharma A/S appears more favorable than CRISPR Therapeutics AG, based on analyst opinion.

Institutional & Insider Ownership

CRISPR Therapeutics AG and Zealand Pharma A/S has shares held by institutional investors as follows: 50% and 9%. Insiders held roughly 2% of CRISPR Therapeutics AG’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 3.15% 6.25% 30.58% 57.23% 7.51% 77.42%
Zealand Pharma A/S -1.05% 3.57% 8.69% 53.95% 52.19% 94.92%

For the past year CRISPR Therapeutics AG’s stock price has smaller growth than Zealand Pharma A/S.

Summary

Zealand Pharma A/S beats on 8 of the 11 factors CRISPR Therapeutics AG.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.




Source link